ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID‐19
Background COVID‐19 is caused by the coronavirus SARS‐CoV‐2, which uses angiotensin‐converting enzyme 2 (ACE‐2) as a receptor for cellular entry. It is theorized that ACE inhibitors (ACE‐Is) or angiotensin receptor blockers (ARBs) may increase vulnerability to SARS‐CoV‐2 by upregulating ACE‐2 expres...
Gespeichert in:
| Veröffentlicht in: | Journal of internal medicine 2021-05, Vol.289 (5), p.688-699 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 699 |
|---|---|
| container_issue | 5 |
| container_start_page | 688 |
| container_title | Journal of internal medicine |
| container_volume | 289 |
| creator | Tetlow, S. Segiet‐Swiecicka, A. O’Sullivan, R. O’Halloran, S. Kalb, K. Brathwaite‐Shirley, C. Alger, L. Ankuli, A. Baig, M.S. Catmur, F. Chan, T. Dudley, D. Fisher, J. Iqbal, M.U. Puczynska, J. Wilkins, R. Bygate, R. Roberts, P. |
| description | Background
COVID‐19 is caused by the coronavirus SARS‐CoV‐2, which uses angiotensin‐converting enzyme 2 (ACE‐2) as a receptor for cellular entry. It is theorized that ACE inhibitors (ACE‐Is) or angiotensin receptor blockers (ARBs) may increase vulnerability to SARS‐CoV‐2 by upregulating ACE‐2 expression, but ACE‐I/ARB discontinuation is associated with clinical deterioration.
Objective
To determine whether ACE‐I and ARB use is associated with acute kidney injury (AKI), macrovascular thrombosis and in‐hospital mortality.
Methods
A retrospective, single‐centre study of 558 hospital inpatients with confirmed COVID‐19 admitted from 1 March to 30 April 2020, followed up until 24 May 2020. AKI and macrovascular thrombosis were primary end‐points, and in‐hospital mortality was a secondary end‐point.
Results
AKI occurred in 126 (23.1%) patients, 34 (6.1%) developed macrovascular thrombi, and 200 (35.9%) died. Overlap propensity score‐weighted analysis showed no significant effect of ACE‐I/ARB use on the risk of occurrence of the specified end‐points. On exploratory analysis, severe chronic kidney disease (CKD) increases odds of macrovascular thrombi (OR: 8.237, 95% CI: 1.689–40.181, P = 0.009). The risk of AKI increased with advancing age (OR: 1.028, 95% CI: 1.011–1.044, P = 0.001) and diabetes (OR: 1.675, 95% CI: 1.065–2.633, P = 0.025). Immunosuppression was associated with lower risk of AKI (OR: 0.160, 95% CI: 0.029–0.886, P = 0.036). Advancing age, dependence on care, male gender and eGFR |
| doi_str_mv | 10.1111/joim.13202 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7753609</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2515039467</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4482-29331980bb78baa364070b5e85f5a58b466117460bc5248f0f1f863a84f4303f3</originalsourceid><addsrcrecordid>eNp9kc9OGzEQh62KqqTApQ9QrcQFVV0Y_13vBQkFaFOBIlWlV8veeInDxg72LlVufQSesU9S01DUcsCXkTzffJrRD6F3GA5xfkeL4JaHmBIgr9AIU8FLUtViC42g5qwUksA2epvSAgBTEPAGbVNKMFBejdDXk_FZ4fzcGdeHmD4W2l-70FufnC-ibewqfxemC82NjSl3Z4X1s9DPbed0lycXQ1znUoyn3yenv37e43oXvW51l-zeY91BV-dn38afy4vpp8n45KJsGJOkJDWluJZgTCWN1lQwqMBwK3nLNZeGCYFxxQSYhhMmW2hxKwXVkrWMAm3pDjreeFeDWdpZY30fdadW0S11XKugnfq_491cXYc7VVWcCqiz4OBREMPtYFOvli41tuu0t2FIijBBGOaAeUb3n6GLMESfz1OEZ4TWTFSZ-rChmhhSirZ9WgaDeohKPUSl_kSV4ff_rv-E_s0mA3gD_HCdXb-gUl-mk8uN9DfMFp3U</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2515039467</pqid></control><display><type>article</type><title>ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID‐19</title><source>MEDLINE</source><source>Wiley Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Tetlow, S. ; Segiet‐Swiecicka, A. ; O’Sullivan, R. ; O’Halloran, S. ; Kalb, K. ; Brathwaite‐Shirley, C. ; Alger, L. ; Ankuli, A. ; Baig, M.S. ; Catmur, F. ; Chan, T. ; Dudley, D. ; Fisher, J. ; Iqbal, M.U. ; Puczynska, J. ; Wilkins, R. ; Bygate, R. ; Roberts, P.</creator><creatorcontrib>Tetlow, S. ; Segiet‐Swiecicka, A. ; O’Sullivan, R. ; O’Halloran, S. ; Kalb, K. ; Brathwaite‐Shirley, C. ; Alger, L. ; Ankuli, A. ; Baig, M.S. ; Catmur, F. ; Chan, T. ; Dudley, D. ; Fisher, J. ; Iqbal, M.U. ; Puczynska, J. ; Wilkins, R. ; Bygate, R. ; Roberts, P.</creatorcontrib><description>Background
COVID‐19 is caused by the coronavirus SARS‐CoV‐2, which uses angiotensin‐converting enzyme 2 (ACE‐2) as a receptor for cellular entry. It is theorized that ACE inhibitors (ACE‐Is) or angiotensin receptor blockers (ARBs) may increase vulnerability to SARS‐CoV‐2 by upregulating ACE‐2 expression, but ACE‐I/ARB discontinuation is associated with clinical deterioration.
Objective
To determine whether ACE‐I and ARB use is associated with acute kidney injury (AKI), macrovascular thrombosis and in‐hospital mortality.
Methods
A retrospective, single‐centre study of 558 hospital inpatients with confirmed COVID‐19 admitted from 1 March to 30 April 2020, followed up until 24 May 2020. AKI and macrovascular thrombosis were primary end‐points, and in‐hospital mortality was a secondary end‐point.
Results
AKI occurred in 126 (23.1%) patients, 34 (6.1%) developed macrovascular thrombi, and 200 (35.9%) died. Overlap propensity score‐weighted analysis showed no significant effect of ACE‐I/ARB use on the risk of occurrence of the specified end‐points. On exploratory analysis, severe chronic kidney disease (CKD) increases odds of macrovascular thrombi (OR: 8.237, 95% CI: 1.689–40.181, P = 0.009). The risk of AKI increased with advancing age (OR: 1.028, 95% CI: 1.011–1.044, P = 0.001) and diabetes (OR: 1.675, 95% CI: 1.065–2.633, P = 0.025). Immunosuppression was associated with lower risk of AKI (OR: 0.160, 95% CI: 0.029–0.886, P = 0.036). Advancing age, dependence on care, male gender and eGFR < 60 mL min−1/1.73 m2 increased odds of in‐hospital mortality.
Conclusion
We did not identify an association between ACE‐I/ARB use and AKI, macrovascular thrombi or mortality. This supports the recommendations of the European and American Societies of Cardiology that ACE‐Is and ARBs should not be discontinued during the COVID‐19 pandemic.</description><identifier>ISSN: 0954-6820</identifier><identifier>EISSN: 1365-2796</identifier><identifier>DOI: 10.1111/joim.13202</identifier><identifier>PMID: 33210357</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>ACE inhibitors ; Acute Kidney Injury - diagnosis ; Acute Kidney Injury - etiology ; Age Factors ; Aged ; Angiotensin Receptor Antagonists - therapeutic use ; Angiotensin-converting enzyme inhibitors ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Cardiology ; Clinical deterioration ; Comorbidity ; Coronaviruses ; COVID-19 ; COVID-19 - diagnosis ; COVID-19 - mortality ; COVID-19 - physiopathology ; critical care ; Diabetes mellitus ; Diabetes Mellitus - epidemiology ; endothelial function ; Epidermal growth factor receptors ; Female ; Glomerular Filtration Rate ; Hospital Mortality ; Humans ; Hypertension - drug therapy ; Hypertension - epidemiology ; Immunosuppression ; infectious disease ; Inhibitors ; Kidney diseases ; Kidneys ; Male ; Mortality ; Original ; Outcome and Process Assessment, Health Care ; Pandemics ; Receptors ; renal failure ; Renal Insufficiency, Chronic - epidemiology ; Renal Insufficiency, Chronic - therapy ; Risk ; Risk Adjustment - methods ; SARS-CoV-2 - isolation & purification ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Thromboembolism ; Thrombosis ; Thrombosis - diagnosis ; Thrombosis - etiology ; United Kingdom - epidemiology ; Viral diseases ; Withholding Treatment - standards ; Withholding Treatment - statistics & numerical data</subject><ispartof>Journal of internal medicine, 2021-05, Vol.289 (5), p.688-699</ispartof><rights>2020 The Association for the Publication of the Journal of Internal Medicine</rights><rights>2020 The Association for the Publication of the Journal of Internal Medicine.</rights><rights>Copyright © 2021 The Association for the Publication of the Journal of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4482-29331980bb78baa364070b5e85f5a58b466117460bc5248f0f1f863a84f4303f3</citedby><cites>FETCH-LOGICAL-c4482-29331980bb78baa364070b5e85f5a58b466117460bc5248f0f1f863a84f4303f3</cites><orcidid>0000-0002-3110-1125</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjoim.13202$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjoim.13202$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33210357$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tetlow, S.</creatorcontrib><creatorcontrib>Segiet‐Swiecicka, A.</creatorcontrib><creatorcontrib>O’Sullivan, R.</creatorcontrib><creatorcontrib>O’Halloran, S.</creatorcontrib><creatorcontrib>Kalb, K.</creatorcontrib><creatorcontrib>Brathwaite‐Shirley, C.</creatorcontrib><creatorcontrib>Alger, L.</creatorcontrib><creatorcontrib>Ankuli, A.</creatorcontrib><creatorcontrib>Baig, M.S.</creatorcontrib><creatorcontrib>Catmur, F.</creatorcontrib><creatorcontrib>Chan, T.</creatorcontrib><creatorcontrib>Dudley, D.</creatorcontrib><creatorcontrib>Fisher, J.</creatorcontrib><creatorcontrib>Iqbal, M.U.</creatorcontrib><creatorcontrib>Puczynska, J.</creatorcontrib><creatorcontrib>Wilkins, R.</creatorcontrib><creatorcontrib>Bygate, R.</creatorcontrib><creatorcontrib>Roberts, P.</creatorcontrib><title>ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID‐19</title><title>Journal of internal medicine</title><addtitle>J Intern Med</addtitle><description>Background
COVID‐19 is caused by the coronavirus SARS‐CoV‐2, which uses angiotensin‐converting enzyme 2 (ACE‐2) as a receptor for cellular entry. It is theorized that ACE inhibitors (ACE‐Is) or angiotensin receptor blockers (ARBs) may increase vulnerability to SARS‐CoV‐2 by upregulating ACE‐2 expression, but ACE‐I/ARB discontinuation is associated with clinical deterioration.
Objective
To determine whether ACE‐I and ARB use is associated with acute kidney injury (AKI), macrovascular thrombosis and in‐hospital mortality.
Methods
A retrospective, single‐centre study of 558 hospital inpatients with confirmed COVID‐19 admitted from 1 March to 30 April 2020, followed up until 24 May 2020. AKI and macrovascular thrombosis were primary end‐points, and in‐hospital mortality was a secondary end‐point.
Results
AKI occurred in 126 (23.1%) patients, 34 (6.1%) developed macrovascular thrombi, and 200 (35.9%) died. Overlap propensity score‐weighted analysis showed no significant effect of ACE‐I/ARB use on the risk of occurrence of the specified end‐points. On exploratory analysis, severe chronic kidney disease (CKD) increases odds of macrovascular thrombi (OR: 8.237, 95% CI: 1.689–40.181, P = 0.009). The risk of AKI increased with advancing age (OR: 1.028, 95% CI: 1.011–1.044, P = 0.001) and diabetes (OR: 1.675, 95% CI: 1.065–2.633, P = 0.025). Immunosuppression was associated with lower risk of AKI (OR: 0.160, 95% CI: 0.029–0.886, P = 0.036). Advancing age, dependence on care, male gender and eGFR < 60 mL min−1/1.73 m2 increased odds of in‐hospital mortality.
Conclusion
We did not identify an association between ACE‐I/ARB use and AKI, macrovascular thrombi or mortality. This supports the recommendations of the European and American Societies of Cardiology that ACE‐Is and ARBs should not be discontinued during the COVID‐19 pandemic.</description><subject>ACE inhibitors</subject><subject>Acute Kidney Injury - diagnosis</subject><subject>Acute Kidney Injury - etiology</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Angiotensin Receptor Antagonists - therapeutic use</subject><subject>Angiotensin-converting enzyme inhibitors</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Cardiology</subject><subject>Clinical deterioration</subject><subject>Comorbidity</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 - mortality</subject><subject>COVID-19 - physiopathology</subject><subject>critical care</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>endothelial function</subject><subject>Epidermal growth factor receptors</subject><subject>Female</subject><subject>Glomerular Filtration Rate</subject><subject>Hospital Mortality</subject><subject>Humans</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - epidemiology</subject><subject>Immunosuppression</subject><subject>infectious disease</subject><subject>Inhibitors</subject><subject>Kidney diseases</subject><subject>Kidneys</subject><subject>Male</subject><subject>Mortality</subject><subject>Original</subject><subject>Outcome and Process Assessment, Health Care</subject><subject>Pandemics</subject><subject>Receptors</subject><subject>renal failure</subject><subject>Renal Insufficiency, Chronic - epidemiology</subject><subject>Renal Insufficiency, Chronic - therapy</subject><subject>Risk</subject><subject>Risk Adjustment - methods</subject><subject>SARS-CoV-2 - isolation & purification</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><subject>Thrombosis - diagnosis</subject><subject>Thrombosis - etiology</subject><subject>United Kingdom - epidemiology</subject><subject>Viral diseases</subject><subject>Withholding Treatment - standards</subject><subject>Withholding Treatment - statistics & numerical data</subject><issn>0954-6820</issn><issn>1365-2796</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9OGzEQh62KqqTApQ9QrcQFVV0Y_13vBQkFaFOBIlWlV8veeInDxg72LlVufQSesU9S01DUcsCXkTzffJrRD6F3GA5xfkeL4JaHmBIgr9AIU8FLUtViC42g5qwUksA2epvSAgBTEPAGbVNKMFBejdDXk_FZ4fzcGdeHmD4W2l-70FufnC-ibewqfxemC82NjSl3Z4X1s9DPbed0lycXQ1znUoyn3yenv37e43oXvW51l-zeY91BV-dn38afy4vpp8n45KJsGJOkJDWluJZgTCWN1lQwqMBwK3nLNZeGCYFxxQSYhhMmW2hxKwXVkrWMAm3pDjreeFeDWdpZY30fdadW0S11XKugnfq_491cXYc7VVWcCqiz4OBREMPtYFOvli41tuu0t2FIijBBGOaAeUb3n6GLMESfz1OEZ4TWTFSZ-rChmhhSirZ9WgaDeohKPUSl_kSV4ff_rv-E_s0mA3gD_HCdXb-gUl-mk8uN9DfMFp3U</recordid><startdate>202105</startdate><enddate>202105</enddate><creator>Tetlow, S.</creator><creator>Segiet‐Swiecicka, A.</creator><creator>O’Sullivan, R.</creator><creator>O’Halloran, S.</creator><creator>Kalb, K.</creator><creator>Brathwaite‐Shirley, C.</creator><creator>Alger, L.</creator><creator>Ankuli, A.</creator><creator>Baig, M.S.</creator><creator>Catmur, F.</creator><creator>Chan, T.</creator><creator>Dudley, D.</creator><creator>Fisher, J.</creator><creator>Iqbal, M.U.</creator><creator>Puczynska, J.</creator><creator>Wilkins, R.</creator><creator>Bygate, R.</creator><creator>Roberts, P.</creator><general>Blackwell Publishing Ltd</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3110-1125</orcidid></search><sort><creationdate>202105</creationdate><title>ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID‐19</title><author>Tetlow, S. ; Segiet‐Swiecicka, A. ; O’Sullivan, R. ; O’Halloran, S. ; Kalb, K. ; Brathwaite‐Shirley, C. ; Alger, L. ; Ankuli, A. ; Baig, M.S. ; Catmur, F. ; Chan, T. ; Dudley, D. ; Fisher, J. ; Iqbal, M.U. ; Puczynska, J. ; Wilkins, R. ; Bygate, R. ; Roberts, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4482-29331980bb78baa364070b5e85f5a58b466117460bc5248f0f1f863a84f4303f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>ACE inhibitors</topic><topic>Acute Kidney Injury - diagnosis</topic><topic>Acute Kidney Injury - etiology</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Angiotensin Receptor Antagonists - therapeutic use</topic><topic>Angiotensin-converting enzyme inhibitors</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Cardiology</topic><topic>Clinical deterioration</topic><topic>Comorbidity</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 - mortality</topic><topic>COVID-19 - physiopathology</topic><topic>critical care</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>endothelial function</topic><topic>Epidermal growth factor receptors</topic><topic>Female</topic><topic>Glomerular Filtration Rate</topic><topic>Hospital Mortality</topic><topic>Humans</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - epidemiology</topic><topic>Immunosuppression</topic><topic>infectious disease</topic><topic>Inhibitors</topic><topic>Kidney diseases</topic><topic>Kidneys</topic><topic>Male</topic><topic>Mortality</topic><topic>Original</topic><topic>Outcome and Process Assessment, Health Care</topic><topic>Pandemics</topic><topic>Receptors</topic><topic>renal failure</topic><topic>Renal Insufficiency, Chronic - epidemiology</topic><topic>Renal Insufficiency, Chronic - therapy</topic><topic>Risk</topic><topic>Risk Adjustment - methods</topic><topic>SARS-CoV-2 - isolation & purification</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><topic>Thrombosis - diagnosis</topic><topic>Thrombosis - etiology</topic><topic>United Kingdom - epidemiology</topic><topic>Viral diseases</topic><topic>Withholding Treatment - standards</topic><topic>Withholding Treatment - statistics & numerical data</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tetlow, S.</creatorcontrib><creatorcontrib>Segiet‐Swiecicka, A.</creatorcontrib><creatorcontrib>O’Sullivan, R.</creatorcontrib><creatorcontrib>O’Halloran, S.</creatorcontrib><creatorcontrib>Kalb, K.</creatorcontrib><creatorcontrib>Brathwaite‐Shirley, C.</creatorcontrib><creatorcontrib>Alger, L.</creatorcontrib><creatorcontrib>Ankuli, A.</creatorcontrib><creatorcontrib>Baig, M.S.</creatorcontrib><creatorcontrib>Catmur, F.</creatorcontrib><creatorcontrib>Chan, T.</creatorcontrib><creatorcontrib>Dudley, D.</creatorcontrib><creatorcontrib>Fisher, J.</creatorcontrib><creatorcontrib>Iqbal, M.U.</creatorcontrib><creatorcontrib>Puczynska, J.</creatorcontrib><creatorcontrib>Wilkins, R.</creatorcontrib><creatorcontrib>Bygate, R.</creatorcontrib><creatorcontrib>Roberts, P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of internal medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tetlow, S.</au><au>Segiet‐Swiecicka, A.</au><au>O’Sullivan, R.</au><au>O’Halloran, S.</au><au>Kalb, K.</au><au>Brathwaite‐Shirley, C.</au><au>Alger, L.</au><au>Ankuli, A.</au><au>Baig, M.S.</au><au>Catmur, F.</au><au>Chan, T.</au><au>Dudley, D.</au><au>Fisher, J.</au><au>Iqbal, M.U.</au><au>Puczynska, J.</au><au>Wilkins, R.</au><au>Bygate, R.</au><au>Roberts, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID‐19</atitle><jtitle>Journal of internal medicine</jtitle><addtitle>J Intern Med</addtitle><date>2021-05</date><risdate>2021</risdate><volume>289</volume><issue>5</issue><spage>688</spage><epage>699</epage><pages>688-699</pages><issn>0954-6820</issn><eissn>1365-2796</eissn><abstract>Background
COVID‐19 is caused by the coronavirus SARS‐CoV‐2, which uses angiotensin‐converting enzyme 2 (ACE‐2) as a receptor for cellular entry. It is theorized that ACE inhibitors (ACE‐Is) or angiotensin receptor blockers (ARBs) may increase vulnerability to SARS‐CoV‐2 by upregulating ACE‐2 expression, but ACE‐I/ARB discontinuation is associated with clinical deterioration.
Objective
To determine whether ACE‐I and ARB use is associated with acute kidney injury (AKI), macrovascular thrombosis and in‐hospital mortality.
Methods
A retrospective, single‐centre study of 558 hospital inpatients with confirmed COVID‐19 admitted from 1 March to 30 April 2020, followed up until 24 May 2020. AKI and macrovascular thrombosis were primary end‐points, and in‐hospital mortality was a secondary end‐point.
Results
AKI occurred in 126 (23.1%) patients, 34 (6.1%) developed macrovascular thrombi, and 200 (35.9%) died. Overlap propensity score‐weighted analysis showed no significant effect of ACE‐I/ARB use on the risk of occurrence of the specified end‐points. On exploratory analysis, severe chronic kidney disease (CKD) increases odds of macrovascular thrombi (OR: 8.237, 95% CI: 1.689–40.181, P = 0.009). The risk of AKI increased with advancing age (OR: 1.028, 95% CI: 1.011–1.044, P = 0.001) and diabetes (OR: 1.675, 95% CI: 1.065–2.633, P = 0.025). Immunosuppression was associated with lower risk of AKI (OR: 0.160, 95% CI: 0.029–0.886, P = 0.036). Advancing age, dependence on care, male gender and eGFR < 60 mL min−1/1.73 m2 increased odds of in‐hospital mortality.
Conclusion
We did not identify an association between ACE‐I/ARB use and AKI, macrovascular thrombi or mortality. This supports the recommendations of the European and American Societies of Cardiology that ACE‐Is and ARBs should not be discontinued during the COVID‐19 pandemic.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>33210357</pmid><doi>10.1111/joim.13202</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-3110-1125</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-6820 |
| ispartof | Journal of internal medicine, 2021-05, Vol.289 (5), p.688-699 |
| issn | 0954-6820 1365-2796 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7753609 |
| source | MEDLINE; Wiley Journals; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection) |
| subjects | ACE inhibitors Acute Kidney Injury - diagnosis Acute Kidney Injury - etiology Age Factors Aged Angiotensin Receptor Antagonists - therapeutic use Angiotensin-converting enzyme inhibitors Angiotensin-Converting Enzyme Inhibitors - therapeutic use Cardiology Clinical deterioration Comorbidity Coronaviruses COVID-19 COVID-19 - diagnosis COVID-19 - mortality COVID-19 - physiopathology critical care Diabetes mellitus Diabetes Mellitus - epidemiology endothelial function Epidermal growth factor receptors Female Glomerular Filtration Rate Hospital Mortality Humans Hypertension - drug therapy Hypertension - epidemiology Immunosuppression infectious disease Inhibitors Kidney diseases Kidneys Male Mortality Original Outcome and Process Assessment, Health Care Pandemics Receptors renal failure Renal Insufficiency, Chronic - epidemiology Renal Insufficiency, Chronic - therapy Risk Risk Adjustment - methods SARS-CoV-2 - isolation & purification Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Thromboembolism Thrombosis Thrombosis - diagnosis Thrombosis - etiology United Kingdom - epidemiology Viral diseases Withholding Treatment - standards Withholding Treatment - statistics & numerical data |
| title | ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID‐19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T19%3A40%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ACE%20inhibitors,%20angiotensin%20receptor%20blockers%20and%20endothelial%20injury%20in%20COVID%E2%80%9019&rft.jtitle=Journal%20of%20internal%20medicine&rft.au=Tetlow,%20S.&rft.date=2021-05&rft.volume=289&rft.issue=5&rft.spage=688&rft.epage=699&rft.pages=688-699&rft.issn=0954-6820&rft.eissn=1365-2796&rft_id=info:doi/10.1111/joim.13202&rft_dat=%3Cproquest_pubme%3E2515039467%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2515039467&rft_id=info:pmid/33210357&rfr_iscdi=true |